The SARS-CoV-2 pandemic has made it clear: good tests are needed to diagnose and monitor emerging and tropical infectious agents. But the market is difficult to predict and therefore not attractive enough for many manufacturers and investors. Yet the need in the countries of the Global South and in tropical medical research is enormous. Moreover, the few existing tests are often not sufficiently sensitive or specific.
In close collaboration with research groups at BNITM and partner institutions in endemic countries, BNITM staff have developed and brought to market highly sensitive and specific antibody tests for four diseases prioritised by the World Health Organization (WHO): for Zika, Lassa and Crimean-Congo haemorrhagic fevers and COVID-19. They are based on a patented technology that enables the development of test systems with outstanding performance characteristics.